Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.
Study Type
OBSERVATIONAL
Enrollment
2,000
Medizinische Universitaet Graz /ID# 278569
Graz, Styria, Austria
NOT_YET_RECRUITINGMedisch Spectrum Twente /ID# 276695
Enschede, Overijssel, Netherlands
RECRUITINGUniversitatea De Medicină Și Farmacie Victor Babeș /ID# 276720
Timișoara, Timiș County, Romania
RECRUITINGMean Base Infusion Rate
Mean base infusion rate (ml/hour) will be assessed
Time frame: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Mean Low Infusion Rate
Mean low infusion rate (ml/hour) will be assessed
Time frame: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
Mean High Infusion Rate
Mean high infusion rate (ml/hour) will be assessed
Time frame: Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Karolinska University Hospital Solna /ID# 277116
Solna, Stockholm County, Sweden
RECRUITING